<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00171145</url>
  </required_header>
  <id_info>
    <org_study_id>CDAR328A2401</org_study_id>
    <nct_id>NCT00171145</nct_id>
  </id_info>
  <brief_title>A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.</brief_title>
  <official_title>A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess the efficacy of a 12-week treatment with darifenacin in increasing
      warning time, the time from first sensation of urgency to voiding, in patients with OAB.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in warning time at week 12.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in warning time at weeks 2 &amp; 6.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in frequency of urge incontinence episodes.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in frequency of micturitions.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean volume per void.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in frequency of urgency.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life.</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">445</enrollment>
  <condition>Overactive Bladder Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Darifenacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darifenacin</intervention_name>
    <description>Darifenacin 15 mg tablets once daily</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Enablex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets once daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Three symptoms of OAB (urge incontinence, frequency and urgency) for at least six
             months prior to Visit 2.

          -  Patients capable of independent toileting and able of independently completing the
             patient diary.

        Exclusion Criteria:

          -  Patients in whom the use of anticholinergic drugs was contraindicated

          -  Evidence of severe liver disease

          -  Patients with other clinically significant urinary or gynecological conditions

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Chair</role>
    <affiliation>East Hanover NJ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <zip>07936-108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>January 18, 2008</last_update_submitted>
  <last_update_submitted_qc>January 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2008</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Overactive Bladder, incontinence, antimuscarinic, warning time, darifenacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darifenacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

